Medicus Pharma Seeks Orphan Drug Status for SkinJect in Gorlin Syndrome
Event summary
- Medicus Pharma submitted an Orphan Drug Designation application to the FDA for SkinJect® (D-MNA) to treat basal cell carcinoma in Gorlin Syndrome patients.
- Gorlin Syndrome affects ~11,000 patients in the U.S., qualifying for Orphan Drug Designation benefits.
- SkinJect® is a dissolvable microneedle array delivering doxorubicin directly into BCC lesions.
- The submission follows Phase 1 and 2 clinical studies showing favorable safety and efficacy profiles in broader BCC populations.
The big picture
Medicus Pharma’s Orphan Drug Designation submission for SkinJect in Gorlin Syndrome marks a strategic pivot into a high-unmet-need rare disease indication. The move positions SkinJect as a repeatable, non-surgical alternative in a space dominated by surgical interventions and systemic therapies with tolerability issues. The submission also enhances the program’s attractiveness for potential partners or out-licensing opportunities.
What we're watching
- Regulatory Approval
- Whether the FDA grants Orphan Drug Designation, which would provide 7 years of market exclusivity and other incentives.
- Clinical Expansion
- The pace at which Medicus advances SkinJect into pivotal trials for Gorlin Syndrome, leveraging existing clinical data.
- Strategic Partnerships
- How collaborations with Helix Nanotechnologies and Reliant AI could enhance SkinJect’s development and commercialization potential.
Related topics